The trial will assess the safety and efficacy of the drug in Covid-19 patients. Credit: iXimus from Pixabay.

MGC Pharmaceuticals has received a second human research ethics committee approval in Israel to conduct a clinical trial of natural anti-infective based product ArtemiC in patients with Covid-19.

The approval was provided by the Hillel Yaffe Hospital, while the first approval was from Nazareth Hospital EMMS.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Considered a food supplement, ArtemiC is designed to help address viral infections with inflammatory complications.

The new double-blind, placebo controlled, Phase II trial will assess the safety and efficacy of the drug in Covid-19 patients.

It is expected to start in the coming weeks and will be completed in September this year, with results expected in October. The trial will enrol a total of 50 patients across two sites.

MGC Pharmaceuticals said in a statement: “The trial will evaluate the safety and efficacy of the product, and determine the claims which the product will be able to be sold as a food supplement. Importantly, MGC will own the intellectual property generated from the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The results from the trial will determine the valid claims that can be made in relation to the product, provide data points for future trials and will be material to the commercial discussions the company is currently undertaking with respect to potential supply and sale agreements of the product in the short term.”

The second site is intended to support the previous approval by offering wider statistical data to help in deciding on further testing for potential marketing authorisation approval.

MGC added that available scientific data on Artemisinin and Curcumin properties supports testing of ArtemiC in Covid-19 patients.

The company will also carry out research, manufacture and packaging for commercial orders from its operational facilities in Europe. It also has the approvals to start commercial production.